• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Tissue Factor Pathway Inhibitor in Thrombosis and Beyond

        互联网

        438
        Tissue factor (TF) plays a crucial role in the pathogenesis of thrombotic, vascular, and inflammatory disorders, and thus, the inhibition of this membrane protein provides a unique therapeutic approach for prophylaxis and/or treatment of various diseases. In recent years, tissue-factor pathway inhibitor (TFPI), the only endogenous inhibitor of the TF/FVIIa complex, has been characterized biochemically and pharmacologically. Studies in patients have demonstrated that both TF and TFPI may be indicators for the course and the outcome of cardiovascular and other diseases. Based on experimental and clinical data, TFPI may become an important drug for several clinical indications. TFPI is expected to inhibit the development of postinjury intimal hyperplasia and thrombotic occlusion in atherosclerotic vessels, and to be effective in acute coronary syndromes (ACS) such as unstable angina (UA) and myocardial infarction (MI). Of special interest is the inhibition of TF-mediated processes in sepsis and disseminated intravascular coagulation, which are associated with the activation of various inflammatory pathways as well as the coagulation system. A phase II trial of the efficacy of TFPI in patients with severe sepsis showed a mortality reduction in TFPI- compared to placebo-treated patients and an improvement of organ dysfunctions. TFPI can be administered exogenously in high doses to suppress TF-mediated effects, or high amounts of TFPI can be released from intravascular stores by other drugs such as heparin and low molecular weight heparins (LMWHs). In this way, high concentrations of the inhibitor are provided at sites of tissue damage and ongoing thrombosis. At present clinical studies with TFPI are rather limited, and the clinical potential of the drug cannot be evaluated properly. However, TFPI and its variants are expected to undergo further development and to find indications in various clinical states.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序